PIC
CRMD icon

Portland Investment Counsel’s CorMedix CRMD Stock Holding History

Portland Investment Counsel’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-39,000
Closed -$165K – 36
2022
Q4 		$165K Hold
39,000
– – 0.09% 35
2022
Q3 		$110K Buy
+39,000
New +$162K 0.07% 36

Other funds holding CRMD

Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Portland Investment Counsel's CRMD Position: Q1 2023 in Review

Portland Investment Counsel sold out of CorMedix (CRMD) in Q1 2023, closing a stake of 39,000 shares — an estimated $165K sold.

Portland Investment Counsel first reported a position in CRMD in Q3 2022 and held it in 2 quarters. The position peaked at $165K in Q4 2022. 65 funds tracked by Wall St. Rank hold CRMD as of Q1 2023.

  • Portland Investment Counsel reported no remaining CorMedix position as of Q1 2023 after selling out during the quarter.
  • Portland Investment Counsel sold 39,000 CorMedix shares in Q1 2023, an estimated $165K.
  • Portland Investment Counsel first reported a position in CorMedix in Q3 2022 and held it in 2 quarters.
  • Portland Investment Counsel's CorMedix position peaked at $165K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held CorMedix as of Q1 2023.

Based on Portland Investment Counsel's 13F filing for Q1 2023, filed 12 May 2023.